Sanofi-Aventis Canada Inc. v. Teva Canada Limited, 2012 FC 551 (Ramipril*)
Justice Snider - 2012-05-23
Read full decision. Automatically generated summary:
These Reasons for Judgment and Judgment deal with claims of invalidity of s. 8 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the PM (NOC) Regulations or the Regulations) made by Sanofi-Aventis Canada Inc. (Sanofi Canada), Sanofi‑Aventis (Sanofi France) and Sanofi-Aventis Deutschland GmbH (Sanofi Germany) (collectively Sanofi). The issue of validity has been raised as a defence by Sanofi in two actions:
Decision relates to:
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- T-1357-09 - APOTEX INC. v. SCHERING CORPORATION ET AL